IMTM Magdeburg

IMTM (Institut für Molekulare und Translationale Medizin) is a biotechnology company and contract research organization based in Magdeburg, Germany, that specializes in translational medicine. The company focuses on bridging the gap between basic molecular research and clinical application, particularly in the fields of immunology, inflammation, and oncology. IMTM provides a comprehensive suite of services including assay development, high-throughput screening, and preclinical validation of drug candidates. Their internal research is notably centered on the development of novel protease inhibitors, such as dual inhibitors of DPP4 and aminopeptidase N, for treating autoimmune and inflammatory disorders. By leveraging its close ties to academic research, IMTM supports pharmaceutical partners in accelerating the discovery and development of targeted molecular therapies.